Skip to main content
. 2023 Apr 25;12(4):786–796. doi: 10.21037/tlcr-23-121

Figure 3.

Figure 3

Kaplan-Meier analysis of OS in specific subgroups of patients stratified by age (A), ECOG performance status (B), histology (C), brain metastases (D), liver metastases (E), and camrelizumab treatment lines (F). OS, overall survival; NR, not reached; ECOG, Eastern Cooperative Oncology Group; PS, performance status; SCC, squamous cell carcinoma; NSCC, non-squamous cell carcinoma.